Full-Time

Senior Manager

Distribution and Logistics

Posted on 4/16/2025

CSL

CSL

10,001+ employees

Develops biotherapies and influenza vaccines

No salary listed

Senior

Kentucky, USA

Category
Quality Control & Compliance
Supply Chain Management
Operations & Logistics
Required Skills
SAP Products
Risk Management
Data Analysis
Requirements
  • Bachelor’s degree in business, science or related discipline
  • 5+ years' experience in supply chain logistics or related operations
  • Demonstrated leadership and ability to manage remote sites and staff
  • Knowledge of pharmaceutical best practices
  • Proficiency in materials management systems/SAP applications
Responsibilities
  • Plan and manage logistics operations to ensure the efficient flow of goods through development and execution of comprehensive transportation and warehousing strategies, negotiation with vendors, and to oversee scheduling processes which optimize the cost-effectiveness and timeliness of supply chain operations.
  • Establish key performance metrics and benchmarks for supply chain planning and forecasting through collaboration with cross-functional teams to set measurable objectives and track outcomes to ensure operational alignment with the company’s strategic priorities.
  • Manage all operations related to distribution, warehousing, and shipping of Seqirus finished goods within the US and ensure Seqirus expectations and requirements for customer service levels are fully achieved. Ensure customer orders are delivered on time, within quality and regulatory specifications, and with no deviations or damages.
  • Manage Seqirus operations at 3rd party distribution centers, including managing all inbound and outbound deliveries, ensuring timeliness of vendor’s throughput and responsiveness, and managing all communications between Seqirus internal groups, such as the Seqirus Customer Service team, and external partners.
  • Interface with Seqirus Customer Service, Commercial Account Managers, manufacturing sites, and internal Global Logistics groups with the intention to foster teamwork and continuous process improvements. Perform regular meetings and reviews in conjunction with respective Logistics and other Seqirus management.
  • Support the long-term strategy and ensure the business is prepared.
  • Lead process improvement initiatives to enhance logistics efficiency using cross-functional teams to map current processes and implement optimized workflows.
  • Manage IT interfaces and respective transactions between Seqirus and 3rd party vendors. This includes ensuring data is being transmitted accurately and in timely manner. Ensure that those systems are designed and operated to meet all Seqirus requirements. Manage IT related issues as they occur to ensure quick and efficient resolution. Ensure all data is captured as required, filed appropriately, and accurate to meet all industry, regulatory and quality requirements.
  • Manage compliance projects related to government regulations for pharmaceutical logistics. Collaborate with legal and quality assurance teams, review protocols, and conduct audits which will ensure compliance with evolving regulatory requirements.
  • Review personnel and operations continuously to identify opportunities for improvement in any or all aspects of logistics operations. Ensure continuity of service is provided to US Distribution ‘customers’ during planned and unplanned absences and that the team works in a respectful, professional, and collaborative manner at all times.
  • Ensure all US Distribution risks are known to the extent possible, identified and adequate mitigation measures are in place. Participate in regular risk register reviews to provide input and status updates on action items. Ensure business continuity plans are in place to secure distribution of Seqirus products in the US in emergency situations.
  • Ensure all key performance indicators (KPIs) and statistics related to warehousing and distribution are captured and reported to Seqirus Logistics management in the correct format and adhering to the required Timelines.
  • Evaluate supply chain performance against projected costs and timeframes by analyzing data trends, benchmarking performance, and implementing corrective actions to enhance operational efficiency and align with financial goals.
  • Ensure quality and security of the products during transportation process. This includes managing all transportation and logistics partners to ensure they meet Seqirus and industry requirements for transporting the goods in the correct environmental conditions.
  • Ensure external partners are handling operations efficiently and on time. Participate in Supplier Audits as required and ensure audit findings are addressed and documented.
  • In close collaboration with Seqirus Logistics Quality department, ensure all warehousing and distribution operations of Seqirus in the US are GDP compliant. This includes all SOPs and working instructions are compliant, and all required distribution licenses are current.
  • Manage any issues / deviations / investigations / recalls and product technical complaints (PTCs) related to US distribution. Follow up in a timely manner and ensure corrective and/or preventive actions (CAPAs) are performed adequately.
  • Ensure all required FDA regulatory and performance reports are generated accurately and on time. Support the Seqirus Trade Compliance departments in matters related to import or export as required.
  • Develop and manage annual budget for US Distribution cost centers. This includes forecasts and explanations of deviations. Manage and review vendor invoices, monthly spending reports and invoice payments. Ensure accuracy of data and seek and identify opportunities for cost savings. In conjunction with the Director Logistics Americas work with other Seqirus Global Logistics teams on cost saving opportunities across markets.
  • Maintain relationships and contracts with external suppliers. Negotiate terms, monitor compliance, and ensure daily activities align with performance expectations to secure a reliable and high-quality supply chain.

CSL develops and delivers biotherapies and influenza vaccines, focusing on rare and serious diseases. Their products include plasma-derived and recombinant therapies, which are created through extensive research and development. CSL serves a wide range of clients, including healthcare providers and governments, across the Americas, Asia Pacific, and Europe. What sets CSL apart from competitors is its comprehensive portfolio of therapies and its commitment to saving lives, as well as its emphasis on diversity and inclusion within its workforce. The company's goal is to protect health and improve the quality of life for patients worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Simplify Jobs

Simplify's Take

What believers are saying

  • CSL's gene therapy HEMGENIX shows sustained efficacy and safety over four years.
  • KOSTAIVE vaccine demonstrates superior immunogenicity and antibody persistence for up to 12 months.
  • CSL's performance-based reimbursement model for HEMGENIX sets new standards in Germany.

What critics are saying

  • Emerging competition in gene therapy could impact CSL's market share.
  • High costs of gene therapies like HEMGENIX may face pushback from healthcare systems.
  • Reliance on plasma-derived therapies exposes CSL to plasma supply shortages.

What makes CSL unique

  • CSL offers the first gene therapy for hemophilia B, HEMGENIX.
  • CSL's KOSTAIVE is the first self-amplifying mRNA COVID-19 vaccine approved in Europe.
  • CSL's diverse portfolio includes plasma-derived therapies, recombinant therapies, and influenza vaccines.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Company News

PharmiWeb
Apr 14th, 2025
First Patient Treated With Hemgenix® (Etranacogene Dezaparvovec) Gene Therapy For Haemophilia B In Austria

Vienna, Austria – 9 April 2025 - CSL Behring Austria today announced that the first haemophilia B patient in Austria was treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at the Comprehensive Care Center of the University Hospital of Medicine Vienna.HEMGENIX® is the first one-time gene therapy approved in Europe for the treatment of adults with severe and moderately severe haemophilia B, an inherited bleeding disorder caused by the lack of Factor IX (a protein needed to produce blood clots to stop bleeding). It is used in adults without a history of Factor IX inhibitors.1“It is a great opportunity for people with hemophilia B to live a symptom-free life for many years,” explains hematologist Univ.-Prof. Priv.-Doz. Dr Cihan Ay from the Medical University of Vienna, University Clinic for Internal Medicine I Clinical Department for Hematology and Hemostaseology."For the community of affected patients and their families, this represents an enormously significant milestone: the ability to treat hemophilia with gene therapy, and the fact that this option is now available in Austria, is something our community has been eagerly anticipating and hoping for over decades," says Thomas Schindl, MA, Chairman of the Austrian Hemophilia Society (ÖHG)."We are proud and grateful to offer haemophilia B patients in Austria a treatment option that has the potential to transform their lives," said Dr Beate Natmessnig, Managing Director of CSL Behring Austria. "This achievement is the result of outstanding regional and national collaboration among all parties involved and is a strong testament to Austria's innovative capabilities."HEMGENIX® was granted conditional marketing authorisation by the European Commission (EC) for the European Union and European Economic Area in February 2023, following approval from the U.S. Food and Drug Administration (FDA) in November 2022

PharmiWeb
Apr 3rd, 2025
Csl Behring And Gkv-Spitzenverband Agree On Reimbursement Price For Hemgenix® – Europe'S First Gene Therapy For Haemophilia B

Marburg, Germany, 2 April 2025 – CSL Behring and the GKV-Spitzenverband (National Association of Statutory Health Insurance Funds) have successfully concluded negotiations on the reimbursement price of HEMGENIX®. This agreement marks the availability of the first gene therapy approved in Europe for haemophilia B under an innovative, national, success-based reimbursement model, being implemented for the first time in Germany.HEMGENIX® represents significant progress in the treatment of haemophilia B. The aim of this one-time gene therapy is to eliminate the need for regular factor IX infusions, thereby offering patients the possibility of more freedom from prophylaxis and significantly improving their quality of life.1-4 This development not only provides substantial relief for those affected but also has the potential to reduce long-term costs for the healthcare system.‘The performance-based payment model at national level which was agreed with the GKV-Spitzenverband is unique in Germany. It addresses key reimbursement challenges, such as the question of long-term efficacy, which is inherent for any one-time therapy. Reimbursement is linked to treatment success of the individual patient,’ explains Stefan Neudoerfer, CSL Behring's chief negotiator in Germany.Moreover, this reimbursement model reflects the high therapeutic and innovative value of HEMGENIX® and sets new standards for integrating innovative gene therapies into the German healthcare system.‘The agreement on the reimbursement price of HEMGENIX® is a decisive step for the care of people with haemophilia B in Germany. It enables access to a groundbreaking therapy and recognises the long-term medical and economic benefits of gene therapy,’ explains Christian Wieszner, Managing Director of CSL Behring Germany.With this agreement, CSL Behring is underlining its commitment to innovative therapies that sustainably improve the lives of patients

PR Newswire
Feb 14th, 2025
European Commission Approves Csl And Arcturus Therapeutics' Kostaive®, The First Self-Amplifying Mrna Covid-19 Vaccine

- KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months post-vaccination compared to conventional mRNA COVID-19 vaccines in clinical trialsWALTHAM, Mass. and SAN DIEGO, Feb. 14, 2025 /PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced that the European Commission has granted marketing authorization for KOSTAIVE ® (ARCT-154), a self-amplifying mRNA COVID-19 vaccine, for individuals 18 years and older. KOSTAIVE is the first sa-mRNA COVID-19 vaccine to receive approval from the European Commission (EC). KOSTAIVE is currently marketed in Japan against COVID-19

PR Newswire
Feb 7th, 2025
Csl Behring'S Gene Therapy Hemgenix® (Etranacogene Dezaparvovec-Drlb) Four Years Post-Infusion Data Continue To Show Sustained Efficacy And Safety In Adults With Hemophilia B

94 percent of patients eliminated factor IX prophylaxis and remained free of continuous prophylaxis through four years post-treatmentMean factor IX activity levels were sustained at near normal levels of 37% through four years post-treatment, reinforcing the efficacy of HEMGENIX in the treatment of hemophilia BPhase 3 HOPE-B data showed that a one-time treatment with HEMGENIX provided long-term bleed protection as mean adjusted annualized bleeding rate (ABR) for all bleeds was reduced by approximately 90% from lead-in as compared to year fourKING OF PRUSSIA, Pa., Feb. 7, 2025 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one-time infusion of HEMGENIX® (etranacogene dezaparvovec-drlb) for adults living with hemophilia B. In an oral presentation at the 18th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), data showed that through four years, HEMGENIX continues to deliver elevated and sustained factor IX activity levels, can offer long-term and greater bleed protection compared to prophylactic treatment, can eliminate the need for routine factor IX prophylaxis, and maintains a favorable safety profile. Approved in 2022 by the U.S. Food and Drug Administration (FDA), HEMGENIX is the first gene therapy for the treatment of adults with hemophilia B who currently use factor IX prophylaxis therapy, or have current or historical life-threatening bleeding, or have repeated, serious spontaneous bleeding episodes. It is also the only approved gene therapy for hemophilia B that can treat adult patients with and without AAV5 neutralizing antibodies thereby providing the potential for a greater number of eligible patients to be treated."Hemophilia B can cause spontaneous bleeds into the joints, resulting in extreme pain and progressive, arthritis-like damage, which can lead to permanent physical debility," said Steven Pipe, MD, Professor of Pediatrics and Pathology, Laurence A

PharmiWeb
Jan 21st, 2025
First Patients Treated With Hemgenix® (Etranacogene Dezaparvovec) Gene Therapy For Haemophilia B In Denmark

First patients treated with HEMGENIX® (etranacogene dezaparvovec) gene therapy for haemophilia B in Denmark. COPENHAGEN, DENMARK—21 January 2025 — CSL Behring Denmark today announced that the first Danish patients with haemophilia B were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec). HEMGENIX® is the first one-time gene therapy to be approved in Europe for the treatment of adults with severe and moderately severe haemophilia B, an inherited bleeding disorder caused by the lack of Factor IX (a protein needed to produce blood clots to stop bleeding). It is used in adults without a history of Factor IX inhibitors.1

INACTIVE